In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis

1996

Article

Fournet Alain, Ferreira M.E., Rojas de Arias A., Torres de Ortiz S., Fuentes S., Nakayama H., Schinini A., Hocquemiller R.

Antimicrobial Agents and Chemotherapy, 1996, 40 (11), p. 2447-2451 ISSN 0066-4804

The antileishmanial efficacies of 2-n-propylquinoline, chimanines B and D, 2-n-pentylquinoline, 2-phenylquinoline, 2-(3,4-methylenedioxyphenylethyl)quinoline, and two total alkaloidal extracts of Galipea longiflora were evaluated in BALB/c mice infected with Leishmania amazonensis or Leishmania venezuelensis. Animals were treated for 4 to 6 weeks postinfection with a quinoline by the oral route at 50 mg/kg of body weight twice daily for 15 days or by five intralesional injections at intervals of 4 days with a quinoline at 50 mg/kg of body weight. The reference drug, N-methylglucamine antimonate (Glucantime), was administered by subcutaneous or intralesional injection (regimens of 14, 28, or 56 mg of pentavalent antimony per kg of body weight daily). Twice-daily oral treatment with chimanine B at 50 mg/kg resulted in a decrease in lesion weight by 70% (P < 0.001) and a decrease in the parasite loads by 95% (P < 0.001). Five injections of chimanine B at intervals of 4 days reduced the lesion weight by 74% and the parasite loads in the lesion by 90% compared with the values for the group of untreated mice. Subcutaneous administration of N-methylglucamine antimonate at 28 mg of pentavalent antimony kg per day for 15 days reduced the parasite burden by 95% (P < 0.001) and five intralesional injections at the same concentration reduced the parasite burden by 96% (P < 0.001). Other 2-substituted quinolines, 2-n-propylquinoline administered by the oral and intralesional routes, 2-phenylquinoline administered by the oral route, 2-n-pentylquinoline administered by intralesional injection, and two total alkaloidal extracts of G. longiflora administered by the oral route, had intermediate effects. These findings suggest that chimanine B may be chosen as a lead molecule in the development of oral therapy against leishmaniasis. (Résumé d'auteur)

Lutte [052PHLEIS03] ; Substances naturelles : utilisation pharmacologique [076PLAMED03]

LEISHMANIOSE ; TRAITEMENT MEDICAL ; EFFICACITE ; ETUDE EXPERIMENTALE ; PLANTE MEDICINALE ; ANIMAL DE LABORATOIRE ; QUINOLINE ; METHYLGLUCAMINE

Fonds IRD [F B010009661]

fdi:010009661